Other Events ·
On August 5, 2026, Summit Therapeutics announced the expansion of its global clinical development program for…
SMMTSummit Therapeutics Inc.
On August 5, 2026, Summit Therapeutics announced the expansion of its global clinical development program for ivonescimab into urothelial carcinoma (bladder cancer) with the planned initiation of the Phase II/III HARMONi-GU1 trial. This study will evaluate ivonescimab combined with enfortumab vedotin versus pembrolizumab plus enfortumab vedotin as first-line therapy for previously untreated locally advanced or metastatic disease, aiming to enroll approximately 800 patients through Phase III. Global site activations are scheduled to begin in the fourth quarter of 2026. This development adds to Summit's broader ivonescimab program, which includes multiple ongoing and completed Phase III trials across other tumor types such as non-small cell lung cancer and colorectal cancer. Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies for serious unmet medical needs.